JRC Publications Repository

JRC Publications Repository >

Browsing by Author BRUCHERTSEIFER Frank

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 10 to 29 of 93
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2013Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenationWULBRAND Christian; SEIDL C.; GAERTNER F. C.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2010[An(H2O)9](CF3SO3)3 (An=U-Cm, Cf): Exploring Their Stability, Structural Chemistry, and Magnetic Behavior by Experiment and TheoryAPOSTOLIDIS Christos; SCHIMMELPFENNIG Bernd; MAGNANI Nicola; LINDQVIST-REIS Patric; WALTER Olaf; SYKORA Richard; MORGENSTERN Alfred; COLINEAU Eric; CACIUFFO Roberto; KLENZE R., et alArticles in Journals
2009Analysis of DNA double-strand breaks in gastric cancer cells after treatment with 213Bi-immunoconjugatesSEIDL C.; FRANK Annette; PFOST B.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; SENEKOWITSCH-SCHMIDTKE ReingardContributions to Conferences
2011Analysis of Patient Survival in a Phase 1 Trial of Systemic Targeted Alpha Therapy for Metastatic MelanomaALLEN B. J.; SINGLA A; RAJA C.; RIZVI S.; GRAHAM P.; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; MORGENSTERN AlfredArticles in Journals
2013Anti-PSMA labeled liposomes loaded with Actinium-225 for potential alpha-particle radiotherapy of tumor vasculatureBANDEKAR Amey; ZHU Charles; JINDAL Rohit; BANERJEE Sangeeta Ray; POMPER Martin; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SOFOU StavroulaContributions to Conferences
2014Anti-PSMA labeled liposomes loaded with Actinium-225 for potential antivascular alpha-radiotherapyZHU Charles; BANDEKAR Amey; BANERJEE Sangeeta Ray; POMPER Martin; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SOFOU StavroulaContributions to Conferences
2014Anti-tumour immunity induced after alpha irradiationGORIN J; MENAGER J; GOUARD S.; MAUREL C; GUILLOUX Yannick; FAIVRE-CHAUVET A; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; CHEREL M.; DAVODEAU F, et alArticles in Journals
2014Anti–Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular a-Particle Therapy of CancerBANDEKAR Amey; ZHU Charles; JINDAL Rohit; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SOFOU StavroulaArticles in Journals
2012Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting RadioisotopesMORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS ChristosArticles in Journals
2008Bismuth-213 Radioimmunotherapy with C595 Anti¿MUC1 Monoclonal Antibody in an Ovarian Cancer Ascites ModelSONG E.; QU C. F.; RIZVI S.; RAJA C.; BERETOV J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; PERKINS A. D.Articles in Journals
2012Combined 213Bi-DTPA- F3 and paclitaxel treatment of peritoneal spread of human ovarian carcinoma in a mouse model enhances therapeutic efficacy due to enhanced induction of apoptosis and G2/M phase cell-cycle arrestSEIDL C.; VALLON M.; BLECHERT B.; GILBERTZ K.-P.; AICHLER M; FEUCHTINGER A; GÄRTNER Florian; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.Contributions to Conferences
2013Comparative analysis of alpha radioimmunotherapy with bismuth-213-labeled anti-CD138 antibody and Melphalan chemotherapy for the treatment of multiple myeloma.GOUARD S.; PALLARDY A; GASCHET J; FAIVRE-CHAUVET A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; MAUREL C; KRAEBER BODÉRÉ F; BARBET J; DAVODEAU F, et alContributions to Conferences
2014Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy.GOUARD S.; PALLARDY A; GASCHET J; FAIVRE-CHAUVET A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; MAUREL C; MATOUS E; KRAEBER BODÉRÉ F; DAVODEAU F, et alArticles in Journals
2012Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer modelGUSTAFSSON Anna; BAECK Tom; ELGQVIST Joergen; JACOBSSON Lars; HULTBORN Ragnar; ALBERTSSON Per; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; JENSEN Holger; LINDEGREN StureArticles in Journals
2009Cross Sections of the Reaction 231Pa(d,3n)230U for Production of 230U/226Th for Targeted Alpha TherapyMORGENSTERN Alfred; LEBEDA O.; STURSA J.; CAPOTE R.; SIN M.; BRUCHERTSEIFER Frank; ZIELINSKA Barbara; APOSTOLIDIS ChristosArticles in Journals
2008Cross-sections of the Reaction 232Th(p,3n)230Pa for Production of 230U for Targeted Alpha TherapyMORGENSTERN Alfred; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; CAPOTE R.; GOUDER Thomas; SIMONELLI Federica; SIN M.; ABBAS KamelArticles in Journals
2013Decay data measurements on 213Bi using recoil atomsMAROULI MARIA; SULIMAN GABRIEL; POMME Stefaan; VAN AMMEL Raf; JOBBAGY VIKTOR; STROH HEIKO; DIKMEN H.; PAEPEN Jan; DIRICAN A.; BRUCHERTSEIFER Frank, et alArticles in Journals
2008Development and Evaluation of Peptidic Ligands Targeting Tumor-associated Urokinase Plasminogen Activator Receptor (uPAR) for Use in Alpha-emitter Therapy of Disseminated Ovarian CancerKNOER S.; SATO S.; HUBER T.; MORGENSTERN ALFRED; BRUCHERTSEIFER FRANK; SCHMITT M.; KESSLER H.; SENEKOWITSCH-SCHMIDTKE R.; MAGDOLEN V.; SEIDL C.Articles in Journals
2013Development of a high-activity 225Ac/213Bi radionuclide generator for synthesis of clinical doses of 213Bi-labelled biomoleculesBRUCHERTSEIFER Frank; APOSTOLIDIS Christos; MIRZADEH Saed; BOLL Rose; MURPHY Karen; MORGENSTERN AlfredContributions to Conferences
2013Die Alpha-Emitter Radioimmuntherapie des multiplen Myeloms mit 213Bi-CHX-A“-DTPA-anti-CD38 Immunkonjugaten zeigt eine hohe Effizienz im präklinischen Xenograft-ModellTEILUF K; SEIDL C.; BLECHERT B.; GÄRTNER Florian; GILBERTZ K.-P.; FERNANDEZ V; BASSERMANN F; ENDELL J; BOXHAMMER R; AICHLER M, et alContributions to Conferences
Showing results 10 to 29 of 93

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top